Key Highlights

● AbbVie and Genmab reported that their epcoritamab combination reduced the risk of disease progression or death in newly diagnosed lymphoma.

● Genmab's shares surged far more than AbbVie's, reflecting its smaller size and greater sensitivity to single trial results.

● The news came on a weak day for big pharma, with Merck the Dow's worst performer.

AbbVie was in the spotlight on Monday after it and partner Genmab reported that their combination treatment for newly diagnosed lymphoma succeeded in a late-stage study.

A win in blood cancer

AbbVie (NYSE:ABBV) was in focus on Monday, Oct. 5, after the drugmaker and its Danish partner Genmab (NASDAQ:GMAB) reported positive results from a Phase 3 trial in lymphoma.

The study, called EPCORE DLBCL-2, tested epcoritamab, sold under the Brand name Epkinly, added to the standard chemotherapy regimen known as R-CHOP. It enrolled patients with newly diagnosed diffuse large B-cell lymphoma, the most common aggressive form of non-Hodgkin lymphoma. The companies said the combination "reduced the risk of disease progression or death" compared with R-CHOP alone.

A closing move for AbbVie shares was not clearly reported.

Genmab's shares surge

The bigger reaction came in Genmab's US-listed shares, which surged on the news, though reports differed on how far.

The difference makes sense. Genmab is a much smaller company than AbbVie, so a single successful drug trial has a bigger impact on its value. AbbVie is one of the world's largest drugmakers, with a broad portfolio that includes immunology medicines Skyrizi and Rinvoq, so any one trial result tends to move its shares less.

Epcoritamab is a bispecific antibody, a type of drug designed to bind two targets at once. In this case it connects the immune system's T-cells to cancer cells so the body can attack them. Moving it into first-line treatment, the first therapy patients receive after diagnosis, would open up a much larger group of patients than later-stage use.

A tough day for big pharma

AbbVie's news stood out on a weak day for large drugmakers. Health care was the weakest sector at midday. Merck (NYSE:MRK) finished as the worst performer on the Dow Jones Industrial Average, Bristol-Myers Squibb (NYSE:BMY) fell after Leerink Partners downgraded it over pipeline risk, and Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) both slipped.

There were bright spots. Vaxcyte (NASDAQ:PCVX) soared after strong late-stage data for its pneumococcal vaccine, life-science tools makers such as Charles River Laboratories (NYSE:CRL) rallied, and Moderna (NASDAQ:MRNA) climbed ahead of joining the Nasdaq-100.

In a separate development related to AbbVie's older blockbuster Humira, Alvotech (NASDAQ:ALVO) said the FDA approved additional US Manufacturing capacity for SIMLANDI, its biosimilar to Humira, a move it said doubles the drug-substance manufacturing capacity available for the US market.

The wider market

The broader market was firm. The S&P 500 rose 51.23 points to 7,773.95, just shy of its summer record. The Nasdaq Composite climbed 286.45 points to a record close of 27,477.31, and the Dow added 90.94 points to 51,267.90.

The 10-year Treasury Yield climbed to its highest close since 2002, as Inflation worries lingered. Friday's jobs report showed only 29,000 jobs added in September, which cut bets on an October Federal Reserve rate hike.

Traders now see roughly a one-in-four or smaller chance of an October hike, down from better than even a week ago. Inflation signals stayed hot, though: the ISM services prices-paid index rose to its highest level since July 2022. Higher bond yields can weigh on defensive sectors such as health care, which investors often hold for steady dividends.

What to watch

Investors will watch for fuller details of the EPCORE DLBCL-2 results and for any next steps AbbVie and Genmab announce for the combination. AbbVie's next Quarterly Report will offer updates on its oncology and immunology businesses. On the macro calendar, the Federal Reserve releases minutes from its September meeting on Wednesday, Oct. 7, at 2pm ET, and the Fed meets again on Oct. 27-28. Big bank Earnings start Oct. 13.